Upper tract surveillance of patients with high-risk non-muscle invasive bladder cancer: A risk-stratified approach for detecting upper tract urothelial carcinoma recurrence based on long-term follow-up data

Abstract

Objective:

To propose a surveillance approach for upper tract urothelial carcinoma (UTUC) recurrence in high-risk and very high-risk non-muscle invasive bladder cancer (HR NMIBC) patients.

Method:

Retrospective analysis in 2024 of 317 patients diagnosed with HR NMIBC in our centre between 2008 and 2018, including histology, CT urogram (CTU) frequency, radiation dose, UTUC recurrence, outcome, and risk factors for UTUC recurrence.

Results:

A total of 283 patients were included for analysis. Incidence of UTUC recurrence 5.7% (n = 16/283), with 3.5% (n = 10/283) undergoing nephroureterectomy. Mean time from initial diagnosis to UTUC recurrence is 5.2 years. At 5- and 10-year follow-up, UTUC incidence was 3.5% and 2.1%, respectively. No patients diagnosed with UTUC recurrence beyond 10 years. Patients underwent mean 2.2 surveillance CTU every 1.9 years, with 17.7 mSv mean radiation dose per scan. No significant increased risk of UTUC recurrence associated with carcinoma in situ (CIS) at diagnosis (χ² = 0.006, p value = 0.94). Risk of UTUC recurrence significantly increased in patients with recurrent HR NMIBC (27%) versus those without (4%) (relative risk = 7.12, χ² = 20.9, p value < 0.00001).

Conclusion:

Consider surgical fitness and HR NMIBC recurrence status when determining duration of surveillance for patients. We propose biennial CTU in patients fit for nephroureterectomy, continuing up to 10 years if recurrent HR NMIBC, or up to 5 years if recurrence-free.

Level of evidence:

2b – Retrospective cohort study

Keywords

bladder cancer oncology (bladder)radiology oncology other

Get full access to this article

View all access options for this article.

References

EAU Guidelines. Non-muscle-invasive bladder cancer. In: Presented at the EAU annual congress Madrid, May, 2025. https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer

National Institute for Health Care Excellence. Bladder cancer: diagnosis and management. National Institute for Health Care Excellence, 2022.

Nishimura

Miyake

Miyamoto

, et al. Routine surveillance of upper urinary tract imaging for diagnosing upper urinary tract urothelial cancer recurrence in patients with nonmuscle invasive bladder cancer. Adv Urol 2024; 2024: 5894288. https://doi.org/10.1155/2024/5894288

Miyake

Hara

Arakawa

, et al. A clinicopathological study of bladder cancer associated with upper urinary tract cancer. BJU Int 2000; 85(1): 37–41. https://doi.org/10.1046/j.1464-410x.2000.00344.x

Hurle

Losa

Manzetti

, et al. Upper urinary tract tumors developing after treatment of superficial bladder cancer: 7-year follow-up of 591 consecutive patients. Urology 1999; 53(6): 1144–1148. https://doi.org/10.1016/s0090-4295(99)00002-3

Subiela

Rodríguez Faba

Aumatell

, et al. Long-term recurrence and progression patterns in a contemporary series of patients with carcinoma in situ of the bladder with or without associated Ta/T1 disease treated with bacillus Calmette-Guérin: implications for risk-adapted follow-up. Eur Urol Focus 2023; 9(2): 325–332. https://doi.org/10.1016/j.euf.2022.09.007

Herr

HW.

Extravesical tumor relapse in patients with superficial bladder tumors. J Clin Oncol 1998; 16(3): 1099–1102. https://doi.org/10.1200/JCO.1998.16.3.1099

Cowan

NC.

CT urography for hematuria. Nat Rev Urol 2012; 9: 218–226.

Public Health England. Medical radiation: patient doses, https://www.gov.uk/government/publications/medical-radiation-patient-doses/patient-dose-information-guidance (2008, accessed 1 May 2025).

10.

Youssef

Shariat

Lotan

, et al. Prognostic effect of urinary bladder carcinoma in situ on clinical outcome of subsequent upper tract urothelial carcinoma. Urology 2011; 77(4): 861–866.

11.

Muilwijk

Akand

Raskin

, et al. Quality control indicators for transurethral resection of bladder tumor: results from an embedded Belgian multicenter prospective registry. Eur Urol Oncol 2023; 6(4): 422–430.

12.

Mariappan

Johnston

Trail

, et al. Scot BC quality OPS clinical collaborative. Achieving benchmarks for national quality indicators reduces recurrence and progression in non-muscle-invasive bladder cancer. Eur Urol Oncol 2024; 7(6): 1327–1337.